Navigation Links
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

steroid naïve children with asthma, 12-months to eight years of age, were randomized to receive 0.25mg UDB, 0.135mg UDB or placebo twice a day over a 12-week period. The co-primary endpoints evaluated asthma control as assessed by changes from baseline as compared to placebo in nighttime composite symptom scores, and daytime composite symptom scores, both comprised of cough, wheeze and shortness of breath.

Conference Call Details

MAP Pharmaceuticals management will host a conference call at 5:30 p.m. ET today to discuss these results.

You may join the call via telephone at 888-631-5931 (domestic) or 913-312-4375 (international). Access to the live webcast will be available via the Investor Relations section of the Company's Website at http://www.mappharma.com. A replay will also be available within 24 hours for at least seven days following the conference call.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Abou
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
4. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
10. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
11. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NEW YORK , July 25, 2014  Smile ... selected to showcase their Virtual Surgery Simulator among ... 2014, which will take place in Washington, ... for the Performing Arts. "Smile Train ... BioDigital alongside the talented community of innovators in health ...
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... the new Vice President of Business Development. Peter has ... in a number of different business development positions with ... positions were primarily related to business development/sales management and ... 30 years makes him a key and strategic asset ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2
... ANTONIO, Feb. 28, 2011 Advanced Cell Diagnostics, ... clinical study utilizing RNAscope™ technology to detect human ... of head and neck cancer. HPV status determined ... of patient outcome and highly concordant with that ...
... 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... dividend policy for 2011 and beyond and declared that the four ... be $0.15 per share of common stock.  The $0.15 dividends will ... 15 to all stockholders who own shares of PDL on March ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3PDL BioPharma Announces Regular Quarterly Dividend Policy 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Parkulture ... co-founders, professional stuntman and parkour instructor, Jared “JJ” Woods, ... sports competition show, American Ninja Warrior. The show will ... at 9PM and will rerun on the new Esquire ... a long-time Miami resident, has been balancing careers as ...
(Date:7/25/2014)... 2014 The new report “Carbohydrase ... Pharmaceuticals and Others), by Type (Amylases, Cellulases, and ... - Global Trends & Forecasts to 2019", by ... the global Carbohydrase market with analysis of trends, ... segmented and values are forecasted on the basis ...
(Date:7/25/2014)... NJ (PRWEB) July 25, 2014 CarePoint ... Dr. Edward Boylan, has joined our network, CarePoint ... the community. Hundreds of highly skilled and experienced physicians ... top doctors and practices in Hudson County, representing a ... Health’s commitment to provide the highest quality care to ...
(Date:7/25/2014)... In today’s technological era, every organization ... devices. This benefits the organization in various ways. But ... which can destroy the confidential information and processes of ... Compliance (EGRC) manage and protect the enterprise from various ... loss in dollars to the comp may. The equipment's ...
(Date:7/25/2014)... Eye & Vision has announced the celebration ... by expanding a new specialized ocular and vision service ... clinic. , By acquiring specialized Visual Evoked Potential (VEP) ... problems, patients with vision loss in need of visual ... implementation of this specialized vision testing clinic. The new ...
Breaking Medicine News(10 mins):Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3
... The official journal of the American Neurological Association, examined ... were devastated in FTD//. ,Von Economo neurons ... have evolved in a select group of socially complex ... whales. Across species, VENs are localized to frontal brain ...
... service use among a group of newly homeless adolescents ... if differences existed// among those who had returned home ... that period, 63 percent had returned home, with the ... most youths in the study sought out health care ...
... that 95 percent of Americans have pre marital sex-sex before ... men //and women as far back as the 1940 were ... hundreds of millions of dollars advising young adults to wait ... official disagreed and opined that even if the programs don't ...
... predictions of influenza activity 2-4 weeks in advance in the ... there are outbreaks of influenza any time of the year, ... as a caution to people to opt for preventive measures ... about a future event buy and sell shares based on ...
... and Eugenics were developed by scientists with a vision to ... genes from the gene pool. // ,But now it ... Though it sounds absurd, ‘why should anyone order for a ... dwarfism, it only means making babies like them. ...
... blood to the part of the brain affected is interrupted, ... or die, impairing local brain function. // ... stroke, new blood vessels begin to form, and, like marching ... area to aid the regeneration process. What’s not known is ...
Cached Medicine News:Health News:A Study Finds VENs Devastated in FTD 2Health News:The Outbreak of Influenza is Now Predicted 2Health News:Can Defective Babies Be Made To Order? 2Health News:Cellular Cues Identified for Stroke Recovery 2
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... Keeler ophthalmoscopes are individually adjusted for ... the eye, not on paper. This, along ... infinity focus, ensures that whatever the patient's ... and largest field of view. Lithium-ion technology ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
Medicine Products: